行情

BIOC

BIOC

Biocept
NASDAQ

实时行情|Nasdaq Last Sale

4.040
+0.140
+3.59%
已收盘, 19:58 09/21 EDT
开盘
4.010
昨收
3.900
最高
4.100
最低
3.870
成交量
65.05万
成交额
--
52周最高
8.38
52周最低
3.260
市值
5,948.08万
市盈率(TTM)
-34.0354
分时
5日
1月
3月
1年
5年
Biocept 将在 RAS 靶向药物开发峰会上展示其 Switch-BlockerTM 技术检测罕见癌症突变的能力;股价飙升
Biocept (NASDAQ:BIOC), a leading provider of molecular diagnostic assays and services, will present data on its Target Selector™ assay formats for the ultra-sensitive detection of KRAS mutations using
Benzinga · 20小时前
Biocept 将在 RAS 靶向药物开发峰会上展示数据,展示其 Switch-Blocker(TM) 技术检测罕见癌症突变的能力
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, will present data on its Target Selector(TM) assay formats for the ultra-sensitive detection of KRAS mutations using Switch-Blocker(TM) technology, which provides advan...
Business Wire · 20小时前
Biocept 将于 9 月出席四场虚拟投资者会议
Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences as follows:
Business Wire · 09/07 12:00
Biocept 根据纳斯达克上市规则 5635(c)(4) 报告诱导赠款
SAN DIEGO, September 01, 2021--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new emp...
Business Wire · 09/01 00:00
The Daily Biotech Pulse:Cara 的 Korsuva 获得 FDA 的批准,诺华、Theravance 和 Vertex Inks CRISPR 许可协议的临床试验令人失望
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23)
Benzinga · 08/24 12:09
这位分析师刚刚对其 Biocept 公司(纳斯达克股票代码:BIOC)的收益预测进行了大规模升级
Shareholders in Biocept, Inc. ( NASDAQ:BIOC ) may be thrilled to learn that the covering analyst has just delivered a...
Simply Wall St. · 08/22 12:17
投资者对 Biocept 脑脊液检测数据的研究反应积极
Biocept Inc (NASDAQ: BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung cancer patients with leptomeningeal carcinomatosis.
Benzinga · 08/19 15:37
Biocept 的 CNSide 检测从转移性非小细胞肺癌患者的脑脊液中识别肿瘤细胞和可操作的治疗生物标志物
Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer Study to be presented at the Society for
Benzinga · 08/19 12:35
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解BIOC最新的财务预测,通过BIOC每股收益,每股净资产,每股现金流等数据分析Biocept近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测BIOC价格均价为12.00,最高价位12.00,最低价为12.00。
EPS
机构持股
总机构数: 37
机构持股: 161.33万
持股比例: 10.96%
总股本: 1,472.30万
类型机构数股数
增持
6
30.95万
建仓
7
8.46万
减持
4
6.87万
平仓
6
12.77万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.10%
医疗设备和用品
+0.22%
高管信息
Chairman/Director
Samuel Riccitelli
Non-Executive Chairman/Independent Director
Margaret Faye Wilson
President/Chief Executive Officer/Director
Michael Nall
Chief Financial Officer/Chief Operating Officer/Secretary
Timothy Kennedy
Senior Vice President
Michael Dugan
Senior Vice President
Michael Terry
Chief Compliance Officer/General Counsel
Michael Brown
Vice President/Director of Sales
Antonio Paternostro
Other
Gary Marchetti
Other
Tom Nauman
Other
Tim Schofield
Director
David Hale
Director
Antonino Morales
Director
Linda Rubinstein
Independent Director
Marsha Chandler
Independent Director
Bruce Gerhardt
Independent Director
Ivor Royston
暂无数据
BIOC 简况
Biocept Inc是一家早期分子肿瘤诊断公司。该公司开发和商业化循环肿瘤细胞(CTC)和循环肿瘤核酸,包括循环肿瘤脱氧核糖核酸(ctDNA)和循环肿瘤核糖核酸(ctRNA),并使用标准血液样本或液体活检进行检测。其血液和脑脊液(CSF)检测旨在通过识别与进展或转移相关的肿瘤细胞并识别可能使一部分癌症患者获得靶向治疗资格的特定致癌改变,为医疗保健提供者提供信息。该公司的Target-Selector CTC和分子平台提供生物标志物检测和监测功能,只需要患者血液样本或CSF样本即可为治疗决策提供信息。它还通过Aegea Biotechnologies, Inc.(Aegea)提供基于聚合酶链反应(PCR)的用于检测COVID-19病毒的灵敏检测。

微牛提供Biocept Inc(NASDAQ-BIOC)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BIOC股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BIOC股票基本功能。